证券代码：002864 证券简称：盘龙药业 公告编号：2026-005 经立信会计师事务所（特殊普通合伙）审验，并由其出具信会师报字[2023] 第 ZF11235 号验资报告。 二、募集资金管理情况 为了规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者权 益，本公司按照《中华人民共和国公司法》、《中华人民共和国证券法》、《上 市公司募集资金监管规则》、《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作（2025 年修订）》等有关法律、法规和规范性文件 的规定，结合公司实际情况，制定了《募集资金管理制度》，对募集资金实行专 户存储管理。 陕西盘龙药业集团股份有限公司 1 关于注销部分募集资金账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司与保荐机构中泰证券股份有限公司及中国银行股份有限公司西安高新 技术开发区支行、西安银行股份有限公司纺织城支行、招商银行股份有限公司西 安分行于 2023 年 10 月 19 日分别签订了《募集资金三方监管协议》，三方监管 协议与深圳证券交易所三方监管协议范本不存在重大差异，公司 ...

格隆汇2月3日丨盘龙药业(002864.SZ)公布，董事朱文锋先生持有公司股份90,000股（占剔除公司已回购 股份的总股本比例为0.0850%），计划在本公告披露之日起15个交易日后的3个月内，以集中竞价方式 减持本公司股份不超过22,500股（占剔除公司已回购股份的总股本比例为0.0212%）。 ...

陕西盘龙药业集团股份有限公司 关于董事减持股份预披露公告 董事朱文锋先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 陕西盘龙药业集团股份有限公司（以下简称"公司"）董事朱文锋先生持有 公司股份 90,000 股（占剔除公司已回购股份的总股本比例为 0.0850%），计划 在本公告披露之日起 15 个交易日后的 3 个月内，以集中竞价方式减持本公司股 份不超过 22,500 股（占剔除公司已回购股份的总股本比例为 0.0212%）。 证券代码：002864 证券简称：盘龙药业 公告编号：2026-004 5、占剔除公司已回购股份的总股本比例：不超过 0.0212%，且减持数量未 公司近日收到公司董事朱文锋先生出具的《股份减持计划告知函》，现将具 体情况公告如下： 一、股东的基本情况 | 股东名称 | 职务 | 持股数量（股） | 占剔除公司已回购股 份的总股本比例（%） | | --- | --- | --- | --- | | 朱文锋 | 董事 | 90,000 | 0.0850 | 二、本 ...

Group 1 - The core product under development by the company, the flurbiprofen patch, has received approval for clinical trials from the National Medical Products Administration [1] - The flurbiprofen patch, developed by Taisho Pharmaceutical Co., Ltd., was first approved in Japan in July 1998 and is intended for pain relief and anti-inflammatory treatment for conditions such as osteoarthritis and muscle pain [1] - The product is classified as a Class 3 chemical drug and is considered an import substitute with clinical value, as the original drug is not yet available in the domestic market [1] Group 2 - The market for flurbiprofen topical formulations is significant, with sales of flurbiprofen gel patches projected to reach 2.839 billion yuan in 2024 and 2.350 billion yuan in the first three quarters of 2025 [2] - If the clinical trials for the flurbiprofen patch proceed successfully, it is expected to capture market share due to its technological advantages, creating a differentiated competitive landscape [2] - The company aims to enhance its product portfolio in the musculoskeletal field, complementing its core products and establishing a comprehensive "oral + topical" orthopedic solution, which will strengthen its brand and market barriers [2]

Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of the drug Fluorobiphenyl Patch [1] - The product is designed with a controlled-release membrane, featuring a large drug load, low irritation, and reduced risk of skin allergies, making it suitable for chronic pain conditions [2] - The original research product has not yet been launched in the domestic market and is classified as a Class 3 chemical drug [1] Group 2 - The approval of this clinical trial is expected to enhance the company's product portfolio in the musculoskeletal field, complementing its core products and improving its "internal + external" orthopedic solutions [3] - The market for similar products, such as Fluorobiphenyl Gel Patch, is significant, with sales reaching 2.839 billion yuan in 2024 and 2.350 billion yuan in the first three quarters of 2025 [2]

Mergers and Acquisitions - Changling Hydraulic plans to acquire 12% of the company's shares at an offer price of 35.82 yuan per share [1] - Chip导科技 intends to purchase 100% equity of Jishun Technology for 403 million yuan and 17.15% equity of Shunlei Technology [2] Share Buybacks - Lexin Technology plans to repurchase shares worth between 50 million to 100 million yuan for employee stock ownership or equity incentives [3] - XGIMI Technology intends to repurchase shares worth between 50 million to 100 million yuan [3] - Lingyun Optical plans to change the purpose of 348.08 million shares for repurchase and cancel them [3] - Midea Group has spent 1.998 billion yuan to repurchase 0.35% of its shares [4] - GoerTek has spent 1.108 billion yuan to repurchase 1.14% of its shares [4] External Investments and Daily Operations - Weiyuan Co. has launched a 250,000 tons/year electrolyte solvent project [5] - Far East Co. signed contracts worth 3.075 billion yuan in January through its subsidiary [6] - Changchun Gaoxin's subsidiary GS3-007a has received approval for clinical trial application for a drug [7] - Aorui De plans to invest approximately 145 million yuan in purchasing computing power equipment to provide services to clients [7] - Electric Power Water Power intends to raise funds not exceeding 3.604 billion yuan through acquisition loans [7] - Guoneng Rixin plans to increase investment of 17.625 million yuan in controlling Sanas Zhihui to enhance new energy asset operation service capabilities [7] - Science plans to engage in molybdenum processing and sales to secure a stable resource supply for rhenium recycling [7] - Panlong Pharmaceutical has received approval for clinical trials of the drug Fluorobiphenyl Patch [8] - Hongxiang Co. plans to transfer 100% equity of Nantong Hanlan New Energy for 120 million yuan [9] - Daon Co. intends to acquire equity in a Vietnamese company for a total purchase price of approximately 15.737 million USD [10] Performance Changes - Shanghai Yizhong expects a net profit of 64.132 million yuan in 2025, a year-on-year increase of 819.42%, with its core product, injectable paclitaxel polymer micelles, included in the national medical insurance directory [11] - Lianyun Technology anticipates a 20.36% year-on-year increase in net profit in 2025, driven by growth in data storage main control chips [12]

Group 1 - Far East Holdings announced that its subsidiary won a contract order worth 3.075 billion yuan, including contracts for green building cables and smart manufacturing cables [1] - Yifan Pharmaceutical received a drug registration certificate for Vitamin K1 injection, which is used to treat vitamin K deficiency-related bleeding [2] - Guangdong Electric Power A's Maoming Bohua Power Plant's Unit 4 has successfully commenced commercial operation, with a total investment of 7.484 billion yuan and an expected annual power generation of 8.6 billion kWh [4] Group 2 - Longfly Fiber reported that the global fiber optic cable industry market environment is normal, with product price fluctuations needing comprehensive assessment [25] - Shanghai Yizhong's net profit for 2025 increased by 819.42%, with total revenue of 317 million yuan, a growth of 82.72% [22] - Guizhou Power's subsidiary received a government subsidy of 200 million yuan [8] Group 3 - Zhongxing Communications plans to invest 117 million yuan in the Jianxing Zhanlu Fund, which focuses on new information technology and advanced manufacturing [10] - Suwen Electric Power's subsidiary established a joint investment fund with a total commitment of 68.5 million yuan, with Suwen contributing 5 million yuan [26] - ST Kaiyuan announced that its stock may face delisting risk due to expected negative net assets for 2025 [27]

Core Viewpoint - The approval of clinical trials for the drug Fluorobufen patch by the National Medical Products Administration represents a significant advancement for the company in the pain management sector, particularly for musculoskeletal conditions [1] Group 1: Product Development - The Fluorobufen patch, developed by Daiichi Sankyo Co., Ltd., was first approved for sale in Japan on July 23, 1998 [1] - The patch is indicated for pain relief and inflammation for conditions such as osteoarthritis, periarthritis of the shoulder, tendinitis, and muscle pain [1] - The product is classified as a Class 3 chemical drug and has not yet been launched in the domestic market [1] Group 2: Product Features - The patch features a controlled-release membrane design, which allows for a large drug load, low irritation, and reduced risk of skin allergies [1] - It is particularly suitable for chronic pain conditions and scenarios requiring high adhesion and flexibility in patches [1] Group 3: Strategic Implications - Successful development of this project will enhance the company's product portfolio in the musculoskeletal field [1] - The new product will complement the company's core offerings in treatment areas, distribution channels, and target customer groups, thereby strengthening brand and market barriers [1] - The integration of "oral + topical" orthopedic product solutions will be further improved [1]

证券代码：002864 证券简称：盘龙药业 公告编号：2026-003 陕西盘龙药业集团股份有限公司 关于公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，陕西盘龙药业集团股份有限公司（以下简称"公司"）收到国家药品 监督管理局核准签发的《药物临床试验批准通知书》，同意氟比洛芬贴剂开展临 床试验。现将有关情况公告如下： 一、药品相关情况 产品名称：氟比洛芬贴剂 二、药品的其他相关情况 本项目所涉产品氟比洛芬贴剂（规格：每贴含氟比洛芬 40mg（面积 10cm× 14cm，含膏量 1.68g/140cm 2））是由日本大正制药株式会社研发，于 1998 年 7 月 23 日在日本获批上市。适应症为下述疾病及症状的镇痛、消炎：骨关节炎、 肩关节周围炎、腱炎及腱鞘炎、腱周炎、肱骨外上髁炎（如网球肘等）、肌肉痛、 外伤后的肿胀及疼痛，本项目原研尚未在国内上市，注册分类为化学药品 3 类。 公司本次获批临床的产品采用控释膜缓释设计，具有载药量大、刺激性低、 不易引起皮肤过敏等特点。尤其适用于转入慢性期的疼痛疾病和对贴剂的伸缩性 ...

Group 1 - The company, Panlong Pharmaceutical (002864.SZ), has received approval from the National Medical Products Administration for the clinical trial of Flurbiprofen transdermal patch [1] - The approved indications for the clinical trial include pain relief and anti-inflammatory treatment for conditions such as osteoarthritis, periarthritis of the shoulder, tendinitis, tenosynovitis, tendinopathy, lateral epicondylitis (e.g., tennis elbow), muscle pain, and swelling and pain after trauma [1]